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INTRODUCTION
In developed countries, breast cancer is the most commonly 
diagnosed cancer in women [1]. Survival outcomes have im-
proved with early, frequent screening assessments, advances 
in surgery and radiotherapy, evolving hormone therapy (HT), 
and improved chemoimmunotherapy. In the literature, the 
relative survival of women with breast cancer in Europe is re-
ported to be 81.9% at 5 years, over the period 1999–2007 [2].
Currently, many women with breast cancer have become 
long-term survivors. Thus, the risk of developing second ma-
lignant neoplasms (SMNs) has become an important concern 
for patients, their families, and clinicians. Most population-
based studies have shown an overall higher risk of second 
neoplasms in breast cancer survivors than in the general popu-
lation [3-7]. Furthermore, an increased incidence of cancer 
has been observed in different sites, including the contralat-
eral breast, ovary, endometrium, thyroid gland, lung, soft tis-
sue sarcomas, melanoma, leukemia, stomach, and colon [3-
18]. The increased risk of developing a second cancer may be 
related to tumor characteristics [16], therapy approach [8-18], 
or genetic factors [19,20].
In the present study, we performed a nested case-control 
study in a population-based cohort to analyze a large, homo-
geneous cohort of women with breast cancer. We tested the 
correlations of the risk of developing a second tumor to pa-
tient and tumor characteristics at the diagnosis of primary 
breast cancer and therapeutic approach utilized, based on data 
recorded in the Modena Cancer Registry (MCR). 
METHODS
This study had a case-control design, nested within a popu-
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Purpose: Evolving therapies have improved the prognoses of 
patients with breast cancer; and currently, the number of long-
term survivors is continuously increasing. However, these pa-
tients are at increased risk of developing a second cancer. Thus, 
late side effects are becoming an important issue. In this study, 
we aimed to investigate whether patient and tumor characteris-
tics, and treatment type correlate with secondary tumor risk. 
Methods: This case-control study included 305 patients with a 
diagnosed second malignancy after almost 6 months after the 
diagnosis of primary breast cancer and 1,525 controls (ratio 1:5 
of cases to controls) from a population-based cohort of 6,325 
women. The control patients were randomly selected from the 
cohort and matched to the cases according to age at diagnosis, 
calendar period of diagnosis, disease stage, and time of follow-
up. Results: BRCA1 or BRCA2 mutation, human epidermal 
growth factor receptor 2 (HER2)+ status, chemotherapy, and ra-
diotherapy were related to increased risk of developing a sec-
ond cancer, whereas hormonotherapy showed a protective ef-
fect. Chemotherapy, radiotherapy, and estrogenic receptor level 
<10% increased the risk of controlateral breast cancer. HER2+ 
status increased the risk of digestive system and thyroid tumors, 
while BRCA1 or BRCA2 mutation increased the risk of cancer in 
the genital system. Conclusion: Breast cancer survivors are ex-
posed to an excess of risk of developing a second primary can-
cer. The development of excess of malignancies may be related 
either to patient and tumor characteristics, such as BRCA1 or 
BRCA2 mutation and HER2+ status, or to treatments factors.
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lation-based cohort of 6,325 women with a primary, non-
metastatic breast cancer. The women were diagnosed between 
January 1996 and December 2007. The patients were regis-
tered in the MCR, according to the International Classifica-
tion of Disease for Oncology, Third Revision (ICD-O3). Dif-
ferent ICD classifications were used during the period 1996–
2007. Therefore, we converted all cancer codes into ICD-O3 
terms. The International Federation of Gynecology and Ob-
stetrics and the Union for International Cancer Control 
(UICC) tumor, neoplasm, metastasis (TNM) classification of 
malignant tumors (sixth edition) were used for staging the 
disease. Clinical and medical record information, including 
treatment modalities, and tumor characteristics, were con-
verted into a standardized electronic form.
The inclusion criteria for the study were as follows: a diag-
nosis of primary nonmetastatic breast cancer histologically 
confirmed between January 1996 and December 2007, female 
sex, complete information on disease stage and treatment mo-
dalities, and survival for 6 or more months without the devel-
opment of a SMN. Patients were considered to have SMNs 
when second tumors were diagnosed at least 6 months after 
the first primary diagnosis and recorded as code /3 (malig-
nant, primary site) according to the ICD-O3. The SMNs were 
considered microscopically verified when diagnosis was based 
on malignant histologic or cytologic reports, and were classi-
fied according to the ICD-O3 terms. 
Among 6,325 patients with primary, nonmetastatic breast 
cancer, 104 were excluded because they died within 6 months 
of the breast cancer diagnosis, 1,148 were excluded because 
the therapeutic regimens were not reported in the electronic 
form, and 285 were excluded because the stage of disease was 
unknown. Of the remaining 4,788 patients, 4,471 did not de-
velop SMNs and 317 were diagnosed with a SMN during fol-
low-up. Of the 317 patients, 12 were excluded because they 
developed a second cancer within 6 months of the diagnosis. 
In conclusion, we identified 305 cases of second cancers after 
the diagnosis of a primary breast cancer that met the study 
criteria (Figure 1). A detailed list of second cancers is provided 
in Supplementary Table 1 (available online).
The SMNs were classified as head and neck cancer, melano-
104 Excluded because died within
6 months after diagnosis
6,325 Patients identified
427 Secondary primary neoplasm:
•  110 Exclued because the therapeutic 
regimens was unknown
Study sample=1,830
•  305 Cases
•  1,525 Controls
317 Secondary primary neoplasm:
•  12 Exclued as within 6 months of diagnosis
5,794 No secondary primary neoplasm:
•  1,038 Excluded because therapeutic 
regiments was unknown
•  285 Excluded because therapeutic  
stage of disease was unknown
305 Secondary malignant neoplasm
Figure 1. Flow-chart of patients included in the analysis, starting from 6,325 women with primary breast cancer recorded by Modena Cancer Registry 
between 1996 and 2007. 
6,221 Potentially eligible
4,471 No secondary primary neoplasm
utilizated for the selection of the controls
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ma, skin cancer (nonmelanoma), lung cancer (lung, bronchus, 
and trachea), cancer of the digestive system (esophagus, stom-
ach, small intestine, colon, rectum, liver, and pancreas), cancer 
of the genital system (cervix and corpus uteri, ovary, and other 
female genital organs), cancer of the urinary system (kidney 
and bladder), thyroid cancer, hematological malignancies 
(Hodgkin and non-Hodgkin lymphomas, leukemia [acute 
and chronic lymphocytic leukemia, acute and chronic mye-
loid leukemia, and acute monocytic leukemia], myeloma, 
and myeloproliferative and myelodysplastic syndrome), con-
tralateral breast cancer, and other cancers (mesothelioma; soft 
tissue neoplasia, including the heart, other endocrine glands, 
and thymus, and miscellaneous or unspecified neoplasia) 
(Table 1). We conducted a nested case-control study in a pop-
ulation-based cohort by using risk-set sampling, with the fol-
low-up in months as timescale and a case-control ratio of 1:5. 
Thus, for 305 cases, 1,525 control patients were randomly se-
lected from the cohort and matched to the cases according to 
age at diagnosis of breast cancer (four age groups: < 50, 50–59, 
60–69, and ≥ 70 years), calendar period of diagnosis (1996–
1998,1999–2001, 2002–2004, and 2005–2007), and breast 
cancer stage (I–IIb and IIIa–IV). The follow-up duration was 
calculated in months from the diagnosis of primary breast 
cancer to the date of diagnosis of SMNs or to the date of last 
checkup. The characteristics of the 305 cases and 1,525 con-
trols are presented in Table 2. The MCR covered an average 
population of 643,125 habitants in the province of Modena 
between 1996 and 2007, of whom 51.1% were female.
Statistical analysis
For estimating cumulative incidences, follow-up calcula-
tions were started at the date of primary breast cancer diagno-
sis and ended at the date of SMN diagnosis or the date of 
death or last follow-up (December 31, 2009). Cumulative in-
cidences were estimated with the Gooley method for compet-
ing risk, and death from any cause was considered a compet-
ing event [21]. Cumulative incidences were compared by using 
the regression modeling proposed by Fine and Gray [22]. 
The main outcomes were measured by using the conditional 
logistic regression performed to obtain maximum likelihood 
estimates of the odds ratios (ORs) for associations between 
SMNs and the therapeutic procedure and other risk factors 
[23]. In parallel to the case-control study for all second cancer 
cases, we also conducted a case-control study for the different 
SMN groups (described above) with the same data extraction 
forms and procedures. The roles of the therapeutic modalities 
were analyzed by using the following two approaches: (1) 
comparing each individual modality to everything else as ref-
erence group and (2) considering as reference group (chosen 
as the lowest-risk group to develop SMNs) the patients treated 
with HT and chemotherapy after surgery with or without radio-
therapy, and as comparison groups (a) the patients treated 
only surgically or with HT with or without radiotherapy after 
surgery, (b) those treated with radiotherapy after surgery, (c) 
those treated with chemotherapy after surgery, and (d) those 
treated with radiotherapy and chemotherapy after surgery.
Furthermore, we conducted an ancillary case-control study 
to investigate the relationship between human epidermal 
growth factor receptor 2 (HER2) receptor expression and a 
single group of second cancers. All analyses were performed 
by adjusting the factor or exposure of interest with age and 
calendar year of diagnosis of primary breast cancer as continu-
ous covariates. A comparison between categorical variables 
was performed with the chi-square test or Fisher exact test, 
whichever was appropriate. Continuous covariates were anal-
yzed with the nonparametric Mann-Whitney test. All statisti-
cal tests were two-sided, and a p-value < 0.05 was considered 
statistically significant. The ORs and confidence intervals set 
at 95% (95% CI) were determined. All the analyses were per-
formed with the Stata/SE 10.0 package (StataCorp LP, College 
Station, USA).
Table 1. Number of secondary malignancies observed between 1996 





at 8 yr (%)
95% CI
Contralateral breast cancer 69 1.64 1.24–2.12
Digestive system* 55 1.17 0.86–1.55
Nonmelanoma skin 46 1.16 0.84–1.57
Genital system† 42 0.98 0.69–1.37
Urinary system‡ 16 0.43 0.25–0.71
Lung 15 0.31 0.17–0.52
Thyroid 11 0.28 0.15–0.50
Melanoma   7 0.21 0.09–0.43
Head and neck   6 0.19 0.08–0.43
Other§   9 1.77 1.36–2.28
Solid cancer (excluding 
   contralateral breast cancer)
207 4.96 4.27–5.28
Hematological malignanciesII  29 0.65 0.43–0.96
Total 305 7.27 6.42–8.18
Data from 4,776 cases selected from 6,325 women recorded by Modena 
Cancer Registry between 1996 and 2007.
CI=confidence interval.
*Digestive system: esophagus, stomach, small intestine, colon, rectum, liver 
and pancreas; †Genital system: cervix and corpus uteri, ovary, other female 
genital organs; ‡Urinary system: kidney and bladder; §Other: mesothelioma; 
soft tissue neoplasia, including heart, other endocrine, and thymus; and mis-
cellaneous or unspecified neoplasia; IIHematological malignancies: Hodgkin 
and non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute 
and chronic myeloid leukemia, acute monocytic leukemia, myeloma, myelo-
proliferative and myelodysplastic syndrome.
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Table 2. Overall risk of second cancer, adjusted by age and calendar year at diagnosis, by tumor and patients characteristics, and by therapeutic ap-





OR (95% CI) p-value†
Tumour and patients characteristics
   Grading 1–2 184 (62) 968 (66) 1.00
3 112 (38) 500 (34) 1.21 (0.92–1.59) 0.174
Unknown 9 (3) 57 (4) 0.83 (0.42–1.67) 0.610
   Primary tumor size (T) T1mic–T1b 101 (35) 471 (32) 1.00
T1c 119 (41) 646 (44) 0.87 (0.65–1.17) 0.349
T2 71 (24) 353 (24) 0.93 (0.65–1.34) 0.702
Unknown 14 (5) 55 (4) 1.26 (0.64–2.44) 0.503
   ER (%) ≥10 233 (80) 1,212 (82) 1.00
<10 62 (20) 269 (18) 1.19 (0.88–1.62) 0.262
Unknown 10 (3) 44 (3) 1.15 (0.56–2.38) 0.702
   PR (%) ≥10 193 (66) 954 (65) 1.00
 <10 101 (34) 524 (35) 0.95 (0.73–1.24) 0.698
Unknown 11 (4) 47 (3) 1.13 (0.56–2.87) 0.732
   Ki-67 (%) <20 185 (63) 969 (66) 1.00
≥20 108 (37) 488 (34) 1.16 (0.90–1.50) 0.261
Unknown 12 (4) 68 (5) 0.92 (0.48–1.74) 0.793
   HER2‡ Negative 115 (78) 633 (86) 1.00
Positive 32 (22) 102 (14) 1.73 (1.10–2.70) 0.017
Unknown 158 (52) 790 (52) 1.01 (0.65–1.58) 0.957
   Genetic predisposition Sporadic 277 (91) 1,403 (93) 1.00
Fam. 19 (6) 95 (6) 1.04 (0.62–1.73) 0.889
Inher. 7 (2) 12 (1) 3.53 (1.29–9.64) 0.014
Unknown 2 (1) 15 (1) 0.69 (0.17–2.82) 0.601
Therapeutic approach (mutually exclusive)
   Surgery alone No 277 (91) 1,409 (91) 1.00
Yes 28 (9) 116 (9) 1.19 (0.76–1.86) 0.440
   Surgery+CHT No 283 (93) 1,459 (96) 1.00
Yes 22 (7) 66 (4) 1.76 (1.07–2.91) 0.026
   Surgery+RT No 268 (88) 1,388 (91) 1.00
Yes 37 (12) 137 (9) 1.44 (0.96–2.16) 0.078
   Surgery+CHT+RT No 281 (92) 1,423 (93) 1.00
Yes 24 (8) 102 (7) 1.20 (0.74–1.95) 0.464
   Surgery+HT No 258 (85) 1,272 (83) 1.00
Yes 47 (15) 253 (17) 0.88 (0.61–1.27) 0.494
   Surgery+RT+HT No 227 (74) 1,127 (74) 1.00
Yes 78 (26) 398 (26) 0.98 (0.73–1.31) 0.878
   Surgery+CHT+HT No 282 (92) 1,375 (90) 1.00
Yes 23 (8) 150 (10) 0.74 (0.47–1.16) 0.188
   Surgery+CHT+RT+HT No 259 (85) 1,224 (80) 1.00
Yes 46 (15) 301 (20) 0.72 (0.50–1.03) 0.074
   Surgery +/-CHT+/-RT+HT No 111 (36) 423 (28) 1.00
Yes 194 (64)  1,102 (72) 0.66 (0.50–0.86) 0.003
Therapeutic approach
   Surgery+HT+CHT+/-RT 69 (23) 451 (30) 1.00
   Surgery alone/Surgery+HT+/-RT 153 (50) 769 (50) 1.30 (0.93–1.83) 0.125
   Surgery+RT 37 (12) 137 (9) 1.85 (1.15–2.98) 0.011
   Surgery+CHT 22 (7) 66 (4) 2.24 (1.30–3.85) 0.004
   Surgery+CHT+RT 24 (8) 102 (7) 1.58 (0.93–2.70) 0.093
OR=odds ratio; CI=confidence interval; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor; Fam.= familial; the 
woman have at least two first-degree relatives (mother, father, daughter, son, sister, brother) with breast cancer; Inher.= inheritance; mutation of breast cancer gene 
(BRCA1 or BRCA2); CHT=chemotherapy; RT=radiotherapy; HT=hormone therapy.
*Case control 1:5 matched by age group, stage, year of diagnosis of primary breast cancer, using risk set sampling; Multiple conditional logistic regression where 
the factors were adjusted by age and calendar year of diagnosis of primary breast cancer; †p-value were two-sided Wald test; ‡HER2 evaluation was routinely per-
formed from 2001.




In the Modena Cancer Registry, from January 1996 to De-
cember 2007, 6,325 women with primary, nonmetastatic 
breast cancer were registered in accordance with the ICD-
03/3 classification. For the whole population, the median age 
at breast cancer diagnosis was 61 years (range, 22–96 years). 
Figure 1 shows the selection procedure that led to the final co-
hort of patients. In the selected cohort of 4,776 patients, the 
median follow-up period was 6.3 years (range, 1–14 years), 
which corresponded to 30,304 person-years of observation. In 
the 4,776 eligible patients, the 8-year cumulative incidence of 
secondary cancer was 7.3% (95% CI, 6.4–8.2) (Table 1). The 
median age of the 1,830 patients (305 case and 1,525 controls) 
was 64 years at diagnosis of breast cancer. Overall, second 
cancers were diagnosed less than 3 years after the primary 
breast cancer was diagnosed in 40% of the cases. In detail, 
more than 50% of the cases of lung, genital and urinary sys-
tem, thyroid, and lymphoma second cancers were diagnosed 
within 3 years after the diagnosis of the primary breast cancer. 
About 8% of the cases and controls underwent surgery alone. 
The remaining study population were treated with radiother-
apy (RT) and/or chemotherapy (CHT) and/or HT after sur-
gery. However, the therapeutic approach changed during the 
period of 1996–2007. The frequency of RT alone after surgery 
declined from 14% to 3% from the period 1996–1998 to the 
period 2005–2007 (p< 0.001). Over the same period, the fre-
quency of HT, alone or in combination with RT and/or CHT, 
increased from 62% to 84% (p< 0.001). In particular, the fre-
quency of HT in combination with RT after surgery increased 
from 17% in the period 1996–1998 to 43% in the period 
2005–2007 (p < 0.001). The frequency of CHT, alone or in 
combination with RT and/or HT, decreased from 46% to 32% 
from the period 1996–1998 to the period 2005–2007 (p <  
0.001). Furthermore, the frequency of combination treatment 
with CHT and RT decreased during the study period (p=  
0.029). Of the patients treated with CHT alone or in combina-
tion with RT and/or HT, 66% received regimens containing 
cyclophosphamide.
Over the study period, of the 305 patients, 9% were treated 
with surgery alone; 12%, with RT alone; 7%, with CHT alone; 
and 15%, with HT alone, whereas 57% were treated with CHT 
in combination with RT and/or HT. The details of the charac-
teristics of the 305 cases and 1,525 matched controls are re-
ported in Supplementary Table 2 (available online).
The 1,148 patients excluded because the therapeutic regi-
mens were not reported in the electronic form showed a cu-
mulative incidence of second neoplasia of 7.4% at 8 years, 
similar to the 7.3% observed in the 4,776 eligible patients 
(p= 0.499). Furthermore, after adjusting for age, stage, and 
year of diagnosis, no significant differences were found be-
tween the patients excluded and those included in the study 
(p= 0.300). 
Overall risk of a second malignancy
Risk of a second cancer related to tumor and patient characteristics
We found that the risk of SMNs was not affected by the size 
and grading of the primary tumor, the estrogen or progester-
one receptor status, or the proliferation marker, Ki-67 (Table 
2). Only BRCA1 or BRCA2 mutation and HER2 receptor posi-
tivity were related to a higher risk of developing SMNs than 
that of the control group, with ORs of 3.53 (95% CI, 1.29–
9.64) and 1.73 (95% CI, 1.10–2.70), respectively.
Risk of a second cancer related to treatment modalities
The patients treated with CHT alone showed a higher risk 
of developing a second cancer (OR, 1.76; 95% CI, 1.07–2.91) 
(Table 2) than those treated with other modalities. The pa-
tients treated with RT showed a moderate increase in risk 
(OR, 1.44; 95% CI, 0.96–2.16). The patients treated with the 
combination of CHT and RT showed a moderate increase in 
risk, but it was not statistically significant (OR, 1.20; 95% CI, 
0.74–1.95). Treatment with HT tended to reduce the risk of a 
second cancer when used in combination with CHT (OR, 
0.74; 95% CI, 0.47–1.16) and RT plus CHT (OR, 0.72; 95% CI, 
0.50–1.03). By contrast, treatment after surgery with HT alone 
or HT and RT showed a risk of a second cancer comparable 
that with other modalities (OR, 95% CI: 0.88, 0.61–1.27 and 
0.98, 0.73–1.31, respectively). Based on these results, we di-
vided the therapeutic approaches into five groups, as de-
scribed in the Statistical analysis section. With the group 
treated with HT plus CHT and/or RT after surgery as refer-
ence, we observed an excess of risk in the patients treated after 
surgery with CHT alone (OR, 2.24; 95% CI, 1.30–3.85) and 
RT alone (OR, 1.85; 95% CI, 1.15–2.98) and a marginal risk in 
those treated with the combination of RT and CHT (OR, 1.58; 
95% CI, 0.93–2.70).
Site-specific cancer risk
Because the number of secondary cancer cases was low, we 
grouped the cases according to the site of occurrence (Table 
3). Chemotherapy, RT, and CHT plus RT induced an in-
creased risk of contralateral breast cancer, with ORs of 3.50 
(95% CI, 1.31–9.31), 7.82 (95% CI, 2.43–25.1), and 4.11 (95% 
CI, 1.44–11.7), respectively. In addition, low estrogen receptor 
expression level (< 10%) augmented the risk of contralateral 
breast cancer (OR, 1.88; 95% CI, 1.01–3.56). Positive HER2 
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Surgery+HT+CHT+/-RT 1.00 1.00 1.00 1.00
Surgery/Surgery+HT+/-RT 1.55 (0.66–3.66) 1.66 (0.55–4.96) 1.53 (0.70–3.34) 1.19 (0.30–4.79)
Surgery+RT 2.86 (0.79–10.3) 2.37 (0.62–90.7) 3.50 (1.31–9.31) 5.65 (0.76–42.1)
Surgery+CHT 1.86 (0.31–11.0) 2.91 (0.78–10.8) 7.82 (2.43–25.1) 2.43 (0.26–22.3)
Surgery+RT+CHT 0.70 (0.41–7.12) 0.62 (0.16–5.99) 4.11 (1.44–11.7) 0.75 (0.11–4.92)
Surgery+/-RT+/-CHT+HT§ 0.76 (0.38–1.52) 0.73 (0.34–1.54) 0.28 (0.16–0.48) 0.44 (0.12–1.64)
ER <10% 0.82 (0.32–2.13) 1.34 (0.55–3.27) 1.88 (1.01–3.56) 0.84 (0.22–3.22)
PR <10% 1.34 (0.71–2.51) 0.95 (0.45–1.99) 1.16 (0.69–1.95) 0.94 (0.34–2.62)
Ki-67 ≥20% 1.02 (0.55–1.88) 1.28 (0.57–2.90) 1.50 (0.89–2.54) 0.47 (0.15–1.42)
HER2+ 3.64 (1.36–9.79) 3.12 (0.83–11.7) 1.43 (0.50–4.06) 1.28 (0.09–17.0)
Inheritance 3.37 (0.56–20.3) 14.9 (2.06–108) 0.94 (0.13–6.64) -
OR =odds ratio; CI =confidence interval; BC =breast cancer; HT =hormone therapy; CHT =chemotherapy; RT =radiotherapy; ER =estrogen receptor; 
PR=progesterone receptor; HER2=human epidermal growth factor receptor 2; Inheritance=mutation of breast cancer gene (BRCA1 or BRCA2).
*Case control 1:5 matched by age group, stage, year of diagnosis of primary breast cancer, using risk set sampling; Multiple conditional logistic regression where 
the factors were adjusted by age and calendar year of diagnosis of primary breast cancer; †Digestive system: esophagus, stomach, small intestine, colon, rectum, 
liver and pancreas; ‡Genital system: cervix and corpus uteri, ovary, other female genital organs; §Other therapies versus patients treated with hormone therapy with 
any combination (+/-RT and +/-CHT).
receptor expression was associated with a high risk of diges-
tive system cancer (OR, 3.64; 95% CI, 1.36–9.79). The BRCA1 
or BRCA2 mutation determined an augmented risk of genital 
system cancer (OR, 14.9; 95% CI, 2.06–108). Considering 
other site-specific cancers, we observed that HER2 receptor 
positivity was only marginally related to a high risk of thyroid 
tumor (OR, 9.70; 95% CI, 0.70–135; p= 0.090) and tumor of 
the genital system (OR, 3.12; 95% CI, 0.83–11.7; p= 0.092) 
(Table 4). 
DISCUSSION 
Our results demonstrated that only some tumor and patient 
characteristics, including HER2 receptor positivity, low estro-
gen receptor expression level, and BRCA1 or BRCA2 muta-
tion, had an effect on the risk of SMNs. The major drawbacks 
of our study were the exclusion of 1,148 patients because the 
therapeutic regimens were not reported and the possible un-
derpowered analysis in the evaluation of the site-specific can-
cer risk, possibly because of the wide 95% CI associated in 
some analyses. Although retrospective studies are inherently 
limited, our study had the following strengths: it was conduct-
ed within a well-defined cohort; controls were selected by 
random sampling from the overall population, which avoided 
selection bias; the amount of exposure was recorded before 
the development of SMNs, which avoided information bias; 
cases and controls were matched for confounding variables, 
which allowed the study of many exposure factors (i.e., ther-
apeutic regimens, patient and tumor characteristics, BRCA1 
or BRCA2 mutation, and HER2 status); and our nested case-
control study design was optimal for analyzing rare events 
such as SMNs. Furthermore, to avoid the main drawback of 
cancer registries, which typically lack data on patient charac-
teristics, treatments, and follow-up, we integrated cancer reg-
istry data with information on patient and tumor characteris-
tics and treatment modalities, and other medical data ob-
tained from the analyses of medical records.
As expected, CHT significantly increased the risk of SMNs. 
Radiotherapy augmented the risk, but the effect was not sta-
tistically significant. The combination of CHT and RT did not 
significantly alter the risk of SMNs. Adding HT to CHT with 
Table 4. Risk of some site specific second cancer related to HER2 sta-
tus adjusted by age and calendar year at diagnosis of the primary 
breast cancer*
Cases OR 95% CI p-value
Lung 15 1.28 0.10–17.8 0.853
Skin (not melanoma) 46 2.86 0.64–12.7 0.167
Digestive system† 55 3.64 1.36–9.79 0.010
Genital system‡ 42 3.12 0.83–11.7 0.092
Urinary system§ 16 3.60 0.12–653 0.629
Thyroid 11 9.70 0.70–135 0.090
HematologicalII 29 2.22 0.17–28.7 0.542
Contralateral BC 69 1.43 0.50–4.06 0.501
HER2 =human epidermal growth factor receptor 2; OR =odds ratio; 
CI=confidence interval; BC=breast cancer.
*Case control 1:5 matched by age group, stage, year of diagnosis of primary 
breast cancer, using risk set sampling; Multiple conditional logistic regression 
where the factors were adjusted by age and calendar year of diagnosis of pri-
mary breast cancer; †Digestive system: esophagus, stomach, small intestine, 
colon, rectum, liver and pancreas; ‡Genital system: cervix and corpus uteri, 
ovary, other female genital organs; §Urinary system: kidney and bladder; llHe-
matological: Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia Hodgkin 
and, non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute 
and chronic myeloid leukemia, acute monocytic leukemia, myeloma, myelo-
proliferative and myelodysplastic syndrome.
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or without RT tended to reduce the overall risk, but the effect 
was not statistically significant. Nevertheless, all of the women 
treated with HT, alone or in combination with CHT and/or 
RT, showed a decreased risk of developing secondary malig-
nancies (OR, 0.66; p= 0.003) and the protective effect of HT. 
HT is well known to reduce the risk of contralateral breast 
cancer, although some authors [3-5] have reported an in-
creased risk of endometrial and ovarian cancers. Nevertheless, 
our results did not show any effect of HT on the cancers of the 
genital system. Overall, considering as reference group the pa-
tients treated with surgery plus CHT and HT with or without 
RT, we found an excess of risk of developing a second cancer 
in the CHT and CHT+RT treatment groups.
Furthermore, our results showed that CHT, RT, and low es-
trogen receptor expression level increased the risk of contra-
lateral breast cancer. In their study, Bouchardy et al. [16] re-
ported that the risk of contralateral estrogen receptor-negative 
breast cancer increased after a primary ER-negative breast 
cancer. Our data also showed an increased risk of contralateral 
breast cancer, but we did not test the ER status of the second 
cancer. We also found that HER2 receptor positivity was asso-
ciated with a high risk of cancer of the digestive system and 
marginally associated with the risk of developing tumors of 
the thyroid and genital system, and that inheritance status 
(BRCA1 or BRCA2) determined an augmented risk of cancer 
of the genital system. Our result showed an increased, though 
not statistically significant, risk of lung cancer in patients 
treated with RT alone after surgery, probably due to the few 
cases recorded related to the number of factors analyzed. 
Thus, our result is only partially consistent with the results re-
ported by several other studies [14,15] and may be related to 
the size of the radiation fields.
An interesting result, although the data were recorded only 
in about 50% of the cases and controls and then with a prob-
able presence of selection bias, was the relationship between 
HER2 proteins and secondary tumors. HER2 is a tyrosine ki-
nase receptor that is overexpressed in 25% to 30% of human 
breast cancers [24]. Overexpression of HER2 protein has been 
detected in several other human cancers, including ovarian 
[24], lung [25], thyroid [25,26], and gastric cancers [27]. 
Overexpression or constitutive activation of HER2 can stimu-
late many signaling pathways, including mitogen-activated 
protein kinase, phosphoinositide 3-kinase/AK-transforming 
factors, mammalian target of rapamycin, Src kinase, and STAT 
transcription factors [28]. These signaling pathways induce 
cellular proliferation, migration, differentiation, angiogenesis, 
regulation of apoptosis, and cell cycle control [29,30]. We 
found that HER2 positivity in patients with breast cancer was 
associated with increased risk of second tumors in the diges-
tive system and thyroid. We could not definitively explain this 
augmented risk owing to the lack of reference data from con-
trolled clinical trials with long follow-up observation periods.
In conclusion, this case-control study showed that breast 
cancer survivors’ risk of developing a second cancer was relat-
ed to patient and tumor characteristics, genetic factors, and 
therapies received.
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